Mundipharma and CellAct announce new deal for the worldwide development and commercialization of smart chemotherapy CAP7.1

The Mundipharma network of independent associated companies announced that it has acquired from CellAct the worldwide development, commercialization and manufacturing rights to CAP7.1.

BioSight Completed Patient Enrollment and Treatment in its Extended Acute Leukemia Phase I/II Clinical Trial

BioSight, Ltd, a pharmaceutical development company announced completion of last patient treatment in its extended Phase I/II clinical study of BST-236 in acute leukemia patients.

KP415 Phatmacokinetic Single And Multiple Dose Trial Preliminary Results Announced By KemPharm

KemPharm Inc, a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced preliminary results of KP415.109.

Clinerion announces a new technology for patient identification using fully anonymized electronic patient data

Clinerion has filed an international patent application following the PCT route for a new technology for patient search and identification based on the electronic medical records of patients held by hospitals.

Selvita and the leukemia society announce partnership to advance sel120 into phase i for aml patients

Selvita S.A. and The Leukemia Society announced a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukemia (AML).

RedHill Biopharma announces U.S. commercialization agreement for FDA approved GI product esomeprazole strontium delayed-release capsules

RedHill Biopharma Ltd , a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary...

For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
or
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2017 / Editorial Calender please click here

For the latest visit: www.worldpharmatoday.com